Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

NECESSITY · NEw Clinical Endpoints in primary Sjögren’s Syndrome: an Interventional Trial based on stratifYing patients

H2020Status: SIGNED1 January 201931 December 2025EU funding €8,200,000Call H2020-JTI-IMI2-2017-12-two-stage

Primary Sjögren’s syndrome (pSS) is a systemic autoimmune disease (AID) involving 0.5 to 3/1000 persons. The disease affects exocrine glands leading to dryness of the eyes and the mouth and is associated with fatigue and limb pain. In 30% to 50% of the patients, systemic and extra-glandular manifestations may develop. The spectrum of extra-glandular manifestations in pSS is broad and includes vasculitis, peripheral neuropathy, synovitis, kidney involvement and interstitial lung disease. Moreover, pSS patients have a 10 to 20-fold higher risk of developing B cell lymphomas, conferring shorter lifetime expectancy to these patients. Whereas 10 new targeted-immunomodulatory treatments have been marketed for rheumatoid arthritis in the past 20 years, only one drug has been licensed for other systemic AIDs, such as pSS and systemic erythematous lupus in the same period. There are several factors that may hamper the development of successful drugs for AID. Being multi-organ, these AIDs are considerably heterogeneous among individuals both in terms of clinical manifestations and biological disturbances, with, as a consequence, a great difficulty to set-up accurate composite clinical end-points sensitive to change and usable in clinical trials. In this project, our objectives are:• To develop and assess sensitive clinical endpoints, for use in future clinical trials, able to evaluate response to drug treatments in patients with pSS with high disease burden and/or systemic involvement,• To identify and evaluate discriminative biomarkers for stratification of pSS patients predictive of organ involvement and disease progression and thus available for inclusion in clinical trials,• To set-up and perform an original multi-arm multi-stage clinical trial to validate the newly defined pSS endpoints and the identified biomarkers, by maximizing the chance of finding a difference between the placebo arm and the treated arm.

Consortium · 29 organisations

coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

FR · €932,235

participant

ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK

FR · €815,009

participant

GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED

UK

participant

ASSOCIATION FRANCAISE GOUGEROT-SJOGREN

FR · €50,000

participant

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

EL · €130,319

participant

UNIVERSITA DEGLI STUDI DI UDINE

IT · €100,000

participant

NOVARTIS PHARMA AG

CH

participant

UNIVERSITE DE BREST

FR · €427,719

participant

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

FR · €2,729,817

participant

ACADEMISCH ZIEKENHUIS GRONINGEN

NL · €137,661

participant

THE UNIVERSITY OF BIRMINGHAM

UK · €327,402

participant

UNIVERSITY OF NEWCASTLE UPON TYNE

UK · €380,573

participant

HELSE STAVANGER HF

NO · €101,397

participant

INNOVATION ACTA SRL

IT · €300,000

participant

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

ES · €226,675

participant

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

NL · €196,493

participant

INSTITUT PASTEUR

FR · €118,733

participant

KAROLINSKA INSTITUTET

SE · €251,250

participant

UNIVERSITE PARIS CITE

FR · €224,224

thirdParty

HOSPITAL CLINIC DE BARCELONA

ES

thirdParty

UNIVERSITE PARIS-SACLAY

FR

participant

QUEEN MARY UNIVERSITY OF LONDON

UK · €342,941

thirdParty

CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST

FR

participant

INSTITUT DE RECHERCHES INTERNATIONALES SERVIER

FR

participant

HOPITAUX UNIVERSITAIRES DE STRASBOURG

FR · €337,733

participant

FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD M.P.

ES · €50,000

thirdParty

UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK

IE

participant

UNIVERSITETET I BERGEN

NO · €19,819

participant

BRISTOL-MYERS SQUIBB COMPANY CORP

US

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.